AirSeal CardioVascular and Dr. Zayed is highlighted in St. Louis Magazine

Releted Post

AirSeal is selected as a recipient of the first WashU Venture Network Follow-on Investments

April 12, 2025

Our co-founder, Dr. Zayed, was recently interviewed by KMOX Radio

April 1, 2025

AirSeal is awarded a co-investment of $500,000 from Missouri Technology Corporation (MTC)

November 12, 2024

AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award.

November 1, 2024

AirSeal CardioVascular and Dr. Zayed is highlighted in St. Louis Magazine as ‘Ones to Watch: St. Louisans driving disruption in a range of industries’ and TMC blog page

https://www.stlmag.com/business/st-louisans-driving-disruption-range-industries/

https://www.tmc.edu/blog/unveiling-progress-latest-developments-from-tmcis-accelerator-for-healthtech-cohort/

AirSeal is advancing early, accurate diagnosis of cardiovascular diseases through innovative biomarker technology.